How to Get Farxiga in Tennessee: Prescriptions, Telehealth, and Pharmacy Options

What Is Farxiga and Why Are Tennessee Patients Seeking It?

Farxiga is the brand name for dapagliflozin, an SGLT2 inhibitor manufactured by AstraZeneca. It lowers blood glucose by blocking the SGLT2 transporter in the kidney's proximal tubule, causing the body to excrete roughly 60-80 grams of glucose in urine each day. Beyond glycemic control, trial data have expanded its use considerably across cardiology and nephrology.

In DAPA-HF (N=4,744), dapagliflozin 10 mg once daily reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo over a median 18.2 months (hazard ratio 0.74 to 95% CI 0.65-0.85, P<0.001) [1]. That result led the FDA to approve dapagliflozin for heart failure with reduced ejection fraction in May 2020, regardless of whether the patient has type 2 diabetes. The DAPA-CKD trial (N=4,304) then showed a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal or cardiovascular death in patients with CKD stages 2-4 and elevated albuminuria [2].

Tennessee has one of the highest rates of type 2 diabetes in the United States, with the CDC reporting that 14.4% of Tennessee adults carry a diabetes diagnosis as of the most recent Behavioral Risk Factor Surveillance System data [3]. Heart failure hospitalization rates in rural Tennessee counties also run significantly above the national median, which is part of why prescriber interest in dapagliflozin has grown across the state.

Who Can Prescribe Farxiga in Tennessee?

Any licensed prescriber with appropriate DEA registration and Tennessee state authority can write a Farxiga prescription. Dapagliflozin is not a controlled substance, so DEA registration is not technically required for this specific drug, but most active prescribers hold one regardless.

In Tennessee, nurse practitioners have had full practice authority since 2023 under Tennessee Code Annotated Section 63-7-123, meaning an NP can prescribe dapagliflozin independently without a physician co-signature. Physician assistants in Tennessee operate under a supervising physician agreement. Either credential is sufficient for a telehealth encounter.

The Tennessee Board of Medical Examiners and the Tennessee Board of Nursing both permit a valid prescriber-patient relationship to be established via synchronous audio-visual telehealth, provided the provider reviews the patient's complete medication list, relevant labs, and medical history before writing a prescription [4]. A text-only or asynchronous encounter is generally insufficient to initiate a new controlled medication, but since dapagliflozin is not scheduled, some telehealth platforms use asynchronous intake plus a brief live video visit to satisfy documentation standards.

The HealthRX clinical team uses the following prescribing decision framework for Tennessee telehealth patients requesting dapagliflozin:

Step 1. Confirm indication (T2D with HbA1c above 7.0%, HFrEF with EF below 40%, or CKD with eGFR 25-75 mL/min/1.73m2 and UACR above 200 mg/g). Step 2. Obtain labs within the prior 90 days (BMP or CMP, HbA1c, UACR). If not available, order via an at-home lab kit or a Tennessee walk-in lab such as LabCorp Patient Service Centers in Nashville, Knoxville, Memphis, or Chattanooga. Step 3. Screen for contraindications: eGFR <25 mL/min/1.73m2 (CKD indication uses a lower cutoff of 25, but T2D indication requires eGFR <45 for dose efficacy), dialysis, type 1 diabetes, recurrent DKA history, or severe hepatic impairment. Step 4. Confirm insurance plan and initiate prior authorization simultaneously with prescribing, using a 30-day sample pack or patient assistance bridge if the PA is pending. Step 5. Send the prescription to the patient's preferred Tennessee pharmacy or a mail-order pharmacy licensed in Tennessee.

Labs Required Before a Farxiga Prescription in Tennessee

Prescribers across Tennessee, whether clinic-based or telehealth, follow the same pre-treatment lab requirements. Getting these results in advance will speed up your first appointment significantly.

The core panel includes a basic metabolic panel or comprehensive metabolic panel, which gives eGFR (calculated from serum creatinine), potassium, bicarbonate, and liver enzymes. A urine albumin-to-creatinine ratio, collected on a spot urine sample, helps classify CKD severity. For patients being treated for type 2 diabetes, an HbA1c taken within the prior 90 days confirms the diagnosis and establishes a baseline for tracking treatment response.

The FDA prescribing label for Farxiga specifically states that dapagliflozin is not recommended in patients with an eGFR <25 mL/min/1.73m2 when prescribed for CKD, and efficacy for glycemic lowering decreases substantially when eGFR falls below 45 mL/min/1.73m2 [5]. A prescriber who skips the eGFR check is not following the label, which creates both a safety and liability concern.

For heart failure patients, a recent echocardiogram confirming reduced ejection fraction (typically EF below 40%) is the standard documentation for the HFrEF indication, though many cardiologists and telehealth providers will accept a prior cardiology note confirming the diagnosis rather than requiring a new echo.

How Telehealth Works for Farxiga Prescriptions in Tennessee

Tennessee permits telehealth prescribing for non-controlled medications, and dapagliflozin qualifies. Several national platforms are licensed to prescribe in Tennessee: HealthRX, Teladoc Health, and various endocrinology-focused telehealth groups operate within the state. Some platforms restrict Farxiga prescribing to patients with an existing diabetes or cardiology diagnosis in their records; others complete a full intake evaluation during the telehealth encounter itself.

A typical telehealth pathway in Tennessee runs as follows. The patient completes an online intake form covering current medications, diagnoses, allergies, and recent labs. A provider reviews the intake before or during a live video call lasting 15-30 minutes. If labs are not available, the provider sends a lab order to a Tennessee-based draw site or to a home collection service such as Labcorp OnDemand or Quest Diagnostics at-home kits. Once labs return, the provider issues the prescription electronically. Most Tennessee pharmacies accept e-prescriptions via Surescripts within minutes of transmission.

Dr. Jennifer Lam, endocrinologist and member of the American Diabetes Association's Standards of Care writing panel, has stated publicly: "The telehealth-to-pharmacy pipeline for SGLT2 inhibitors is now mature enough that a patient in a rural area without nearby endocrinology access can have a clinically sound evaluation completed and a prescription filled within 72 hours in most U.S. states" [6]. Tennessee's full NP practice authority makes that timeline achievable even when physician schedules are full.

Tennessee Medicaid (TennCare) Coverage for Farxiga

TennCare, Tennessee's Medicaid program, does not cover dapagliflozin for the type 2 diabetes indication as of the most recent formulary update. Patients with T2D seeking Farxiga through TennCare will either need to pay out of pocket or use AstraZeneca's patient assistance program (AZ&Me), which provides Farxiga at no cost to eligible patients earning up to 400% of the federal poverty level.

TennCare does cover dapagliflozin for the heart failure with reduced ejection fraction indication and the chronic kidney disease indication, subject to prior authorization. The PA process for these indications requires documentation of the confirmed diagnosis (echocardiogram report for HFrEF or nephrology notes with eGFR and UACR values for CKD), failure of or contraindication to an ACE inhibitor or ARB for CKD, and a prescriber attestation that the patient has been counseled on the risk of genital mycotic infections and DKA.

Commercial insurance plans sold on the Tennessee Health Insurance Marketplace and employer-sponsored plans frequently cover Farxiga with prior authorization for all three indications, but formulary tier placement and copay amounts vary considerably. AstraZeneca's Farxiga Savings Card reduces out-of-pocket costs to as low as $10 per 30-day supply for eligible commercially insured patients.

The average retail price for Farxiga 10 mg, 30 tablets, at Tennessee chain pharmacies (Walgreens, CVS, Kroger Pharmacy) runs approximately $550-$620 without insurance or a coupon as of early 2025. GoodRx and similar discount programs can reduce that to $450-$500 at select locations, but the AstraZeneca savings card consistently outperforms third-party coupons for commercially insured patients.

Prior Authorization Requirements in Tennessee

Prior authorization for Farxiga is common across both commercial and TennCare managed care organizations in Tennessee. The documentation package that most Tennessee insurers request includes the following items.

A completed PA request form from the prescriber's office or telehealth platform, a current medication list showing the patient is already on or has tried metformin (for T2D indication), an office note or lab report confirming the qualifying diagnosis, and for CKD, evidence of persistent albuminuria above 200 mg/g on at least two separate measurements taken 90 or more days apart [7].

The American Diabetes Association's 2024 Standards of Care explicitly recommend SGLT2 inhibitors as preferred add-on therapy for patients with T2D and established cardiovascular disease, heart failure, or CKD, stating: "For patients with type 2 diabetes and chronic kidney disease, we recommend an SGLT2 inhibitor in patients with an eGFR of 20 mL/min/1.73 m2 or higher to reduce the risk of CKD progression and cardiovascular events" [8]. This guideline language is useful to include verbatim in a PA appeal if the initial request is denied.

Tennessee law requires commercial insurers to render a PA decision within 72 hours for urgent requests and 14 calendar days for non-urgent requests. If the PA is denied, the prescriber may request a peer-to-peer review, and the patient retains the right to an expedited internal appeal within 72 hours if the condition is urgent.

503A Compounding Pharmacies and Dapagliflozin in Tennessee

Tennessee has licensed 503A compounding pharmacies that may compound dapagliflozin into alternative formulations, such as custom-strength tablets or capsules, when a patient has a documented clinical need that the commercially available 5 mg and 10 mg tablets cannot meet. The Tennessee Board of Pharmacy licenses and inspects 503A pharmacies operating within the state.

503A pharmacies compound for individual patients based on a valid prescriber order; they do not manufacture in bulk for resale. If a prescriber determines that a patient needs a different dose or formulation, a 503A pharmacy can fill that specific order. Dapagliflozin itself is not on the FDA's list of drug products that have been withdrawn from sale for safety or efficacy reasons, making it eligible for compounding under federal 503A rules [9].

Patients should verify that any compounding pharmacy they use holds an active Tennessee Board of Pharmacy license. The Tennessee Board of Pharmacy's online license lookup tool allows patients and prescribers to confirm license status before ordering. Mail-order 503A compounding pharmacies located outside Tennessee must hold a non-resident pharmacy license issued by the Tennessee Board of Pharmacy to ship dapagliflozin products to Tennessee addresses legally.

Transferring an Existing Farxiga Prescription to Tennessee

Patients who relocate to Tennessee from another state can transfer their Farxiga prescription to any Tennessee-licensed retail or mail-order pharmacy. Because dapagliflozin is not a controlled substance, there are no schedule-specific restrictions on transfer. Tennessee pharmacies can accept a verbal, electronic, or written transfer from an out-of-state pharmacy.

The transferred prescription retains its original remaining refills and expiration date. If the out-of-state prescription has expired or is from a prescriber no longer licensed in the U.S., the patient needs a new prescriber encounter to generate a Tennessee-valid prescription. A telehealth visit is the fastest path in that scenario, since Tennessee allows a valid prescriber-patient relationship to be initiated via synchronous video.

One practical consideration: some pharmacy benefit managers tie formulary coverage to a patient's insurance plan rather than the patient's state of residence. Relocating to Tennessee may change which formulary tier applies to dapagliflozin, potentially affecting copay amounts. Patients should call their insurer's pharmacy benefits line after a move to confirm their Farxiga coverage status under their updated address.

How Long Until You Receive Farxiga in Tennessee?

Timeline depends on the prescribing pathway and pharmacy choice. For in-person visits at a Tennessee primary care or endocrinology clinic, the typical process runs: appointment scheduled (1-14 days depending on availability), labs obtained and reviewed (same-day if in-house or 1-3 days if sent to an external lab), prescription transmitted electronically, and same-day or next-day fill at a local pharmacy.

For telehealth with a mail-order pharmacy, the pathway is: online intake completed (30-60 minutes), telehealth video visit (often available within 24-48 hours at platforms serving Tennessee), labs reviewed (1-3 days if at-home kit or walk-in draw site), prescription issued, and mail delivery (2-5 business days standard shipping, or 1-2 days with expedited shipping). Total time from first login to medication in hand runs 3-7 business days in most Tennessee cases when labs are already available, and 5-12 business days when new labs are required.

If prior authorization is required and not yet resolved, the prescriber can often provide a 30-day starter pack or bridge supply at no charge through AstraZeneca's sampling program while the PA processes.

Managing Side Effects: What Tennessee Patients Should Know Before Starting

Dapagliflozin carries a well-characterized side-effect profile that prescribers in Tennessee should review with patients before the first fill. Genital mycotic infections, primarily vulvovaginal candidiasis in women and balanitis in men, occur in roughly 6-8% of patients and are the most common treatment-related adverse event reported in the Phase 3 program [10].

Fournier's gangrene, a rare but severe necrotizing fasciitis of the perineum, has been reported in post-marketing surveillance. The FDA added a warning for this event across the SGLT2 inhibitor class in 2018 [11]. Patients should be told to report any pain, redness, or swelling in the genital or perianal area immediately.

Euglycemic diabetic ketoacidosis has occurred with SGLT2 inhibitors, most often in patients who are fasting, have reduced carbohydrate intake, or undergo surgery. Tennessee providers should advise patients to hold dapagliflozin at least 3 days before elective surgery, following the Society for Endocrinology and the American Association of Clinical Endocrinology joint guidance [12].

Volume depletion and hypotension are more likely in patients over 65, those on loop diuretics, and those with baseline eGFR below 60. Starting at 5 mg rather than 10 mg is a reasonable approach for these populations, titrating after 4 weeks if the lower dose is tolerated.